Table 1.
Amplification efficiencies of individual gene assays in the Onco type DX Prostate Cancer Assay reporting the GPS
| Gene Assay | Estimated Amplification Efficiency | Lower 95% CI | Upper 95% CI |
|---|---|---|---|
| ARF1 |
93.9 |
92.8 |
95.0 |
| ATP5E |
90.2 |
88.2 |
92.2 |
| AZGP1 |
88.1 |
86.5 |
89.7 |
| BGN |
92.5 |
90.5 |
94.7 |
| CLTC |
97.2 |
95.9 |
98.6 |
| COL1A1 |
95.4 |
94.5 |
96.3 |
| FAM13C1 |
88.5 |
85.8 |
91.3 |
| FLNC |
96.9 |
94.9 |
99.0 |
| GPS1 |
94.4 |
92.4 |
96.6 |
| GSN |
91.5 |
89.7 |
93.4 |
| GSTM2 |
95.9 |
93.8 |
98.2 |
| KLK2 |
92.4 |
91.7 |
93.1 |
| PGK1 |
89.9 |
88.4 |
91.4 |
| SFRP4 |
93.9 |
91.2 |
96.7 |
| SRD5A2 |
98.7 |
96.3 |
101.4 |
| TPM2 |
100.2 |
98.8 |
101.8 |
| TPX2 | 98.9 | 97.1 | 100.7 |
Estimated amplification efficiencies and 95% confidence intervals for the 17 genes comprising the GPS derived from a 15-point dilution series.